Novo Nordisk A/SNOV
▼ NegativeCompetitionTechnologyrelevance
Eli Lilly has taken share in the injectable GLP-1 market, pressuring Novo's core franchise.
Impact on assets 2
Biotech & Genomic Medicine▼ · 2 stocks
Novo Nordisk A/S
Eli Lilly and CompanyLLY
± MixedCompetitionrelevance
Mentioned only as having taken share in the injectable GLP-1 market, prompting Novo's diversification push.
Theme Impact 2
Off-coverage companies
Related news
Viking's VK2735 Monthly Dosing Preserves Up to 90% Weight Loss as Lilly Shares Rise
Viking Therapeutics reported that patients on its VK2735 obesity drug preserved as much as 97% of prior weight loss with biweekly injections and up to 90% with monthly dosing, compared with 61% for those switched to placebo. The randomized Phase 1 study followed roughly 180 adults after an initial weekly-treatment phase. Eli Lilly shares rose 0.8% to $1,174.37 Tuesday as investors weighed the competitive readout. Lilly's second-quarter revenue surged 48% to $23 billion, powered mainly by rising Mounjaro and Zepbound volumes, and its $1,174.37 share price sits 24.35% below its $1,550 GF Value estimate. Viking's less-frequent schedule is intriguing, but pivotal trials, regulatory clearance, manufacturing scale and payer access still separate promising data from a genuine threat.
▲2
Eli Lilly Begins $6.5 Billion Houston Plant for Oral GLP-1 Foundayo
Eli Lilly has started construction on a US$6.5 billion manufacturing facility in Houston to produce its oral GLP-1 drug Foundayo. The site is focused on supplying Foundayo for obesity treatment as demand for oral GLP-1 therapies grows in the US and abroad. The project includes partnerships for local workforce training in Houston to support specialized pharmaceutical manufacturing roles. Because Foundayo is a small-molecule oral GLP-1 that uses more established manufacturing methods, the plant adds another US API hub for incretin drugs without relying only on the complex biologics plants that competitors like Novo Nordisk use heavily. Analysts have flagged debt levels and policy risk, so investors must judge whether the new capacity truly diversifies supply or deepens exposure to a single franchise.
3impact 4
Roche's Enicepatide Hits Both Phase II Endpoints in Type 2 Diabetes and Obesity
Roche reported encouraging top-line results from a mid-stage study of enicepatide, its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes and overweight or obesity. In the 447-patient phase II CT-388-104 study, enicepatide met both primary endpoints at 48 weeks, delivering dose-dependent reductions in HbA1c and body weight. At the highest titrated dose of 24 mg, enicepatide reduced HbA1c by 2.65% from a baseline of 8.1%, with about 90% of patients achieving an HbA1c of 6.5% or lower and 62% reaching normoglycemia below 5.7%, while mean body-weight loss was 15.5% at 48 weeks with no evidence of a plateau. In patients with poor baseline glycemic control above 8.5%, the 24 mg dose led to an HbA1c reduction of 4.13% at 48 weeks, and the drug was generally well tolerated with discontinuations due to adverse events of 2.0% in the enicepatide groups versus 0% for placebo. Roche is advancing two ongoing phase III studies in chronic weight management, ENITH-1 and ENITH-2, and plans to initiate a phase III glycemic-control program and cardiovascular outcomes trials in the first half of 2027. Separately, Roche announced that the European Commission has approved Susvimo, a ranibizumab 100 mg/mL solution for injection, for the treatment of neovascular age-related macular degeneration, making it the first and only continuous-delivery treatment approved for nAMD in Europe.